DK3653227T5 - Hidtil ukendte polymere hgh-prodrugs - Google Patents

Hidtil ukendte polymere hgh-prodrugs Download PDF

Info

Publication number
DK3653227T5
DK3653227T5 DK19214864.1T DK19214864T DK3653227T5 DK 3653227 T5 DK3653227 T5 DK 3653227T5 DK 19214864 T DK19214864 T DK 19214864T DK 3653227 T5 DK3653227 T5 DK 3653227T5
Authority
DK
Denmark
Prior art keywords
hitherto unknown
hgh products
polymers
unknown polymers
hgh
Prior art date
Application number
DK19214864.1T
Other languages
English (en)
Other versions
DK3653227T6 (da
DK3653227T3 (da
Inventor
Thomas Kurpiers
Harald Rau
Evelyn Exner
Steen Jensen
Torben Lessmann
Thomas Wegge
Alina Hermann
Nina Schubert
Anna Splanemann
Joachim Zettler
Grethe Nørskov Rasmussen
Original Assignee
Ascendis Pharma Endocrinology Div A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51951624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3653227(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ascendis Pharma Endocrinology Div A/S filed Critical Ascendis Pharma Endocrinology Div A/S
Publication of DK3653227T3 publication Critical patent/DK3653227T3/da
Publication of DK3653227T6 publication Critical patent/DK3653227T6/da
Application granted granted Critical
Publication of DK3653227T5 publication Critical patent/DK3653227T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G17/00—Cultivation of hops, vines, fruit trees, or like trees
    • A01G17/005—Cultivation methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G2/00—Vegetative propagation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G7/00—Botany in general
    • A01G7/06—Treatment of growing trees or plants, e.g. for preventing decay of wood, for tingeing flowers or wood, for prolonging the life of plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • C08G65/3348—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing nitrogen in addition to sulfur
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterized by the type of post-polymerisation functionalisation
    • C08G2650/06—Epoxy-capping
DK19214864.1T 2014-11-18 2015-11-17 Hidtil ukendte polymere hgh-prodrugs DK3653227T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14193603 2014-11-18
EP15797642.4A EP3237014B1 (en) 2014-11-18 2015-11-17 Novel polymeric hgh prodrugs

Publications (3)

Publication Number Publication Date
DK3653227T3 DK3653227T3 (da) 2021-02-15
DK3653227T6 DK3653227T6 (da) 2022-04-11
DK3653227T5 true DK3653227T5 (da) 2023-08-21

Family

ID=51951624

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15797642.4T DK3237014T3 (da) 2014-11-18 2015-11-17 Nye polymere høje prodrugs
DK19214864.1T DK3653227T5 (da) 2014-11-18 2015-11-17 Hidtil ukendte polymere hgh-prodrugs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15797642.4T DK3237014T3 (da) 2014-11-18 2015-11-17 Nye polymere høje prodrugs

Country Status (26)

Country Link
US (2) US10799563B2 (da)
EP (3) EP3653227B9 (da)
JP (5) JP6783782B2 (da)
KR (2) KR102608645B1 (da)
AU (3) AU2015348633C1 (da)
BR (1) BR112017009798A8 (da)
CA (1) CA2968282A1 (da)
CY (1) CY1123963T1 (da)
DK (2) DK3237014T3 (da)
ES (2) ES2947818T3 (da)
FI (2) FI3237014T3 (da)
FR (1) FR22C1029I2 (da)
HR (1) HRP20210400T4 (da)
HU (2) HUE053855T2 (da)
IL (2) IL307773A (da)
LT (2) LT3653227T (da)
MX (2) MX2017006113A (da)
NL (1) NL301172I2 (da)
NO (1) NO2022014I1 (da)
PL (1) PL3653227T6 (da)
PT (1) PT3653227T (da)
RS (1) RS61734B2 (da)
RU (1) RU2718664C2 (da)
SG (2) SG11201703870UA (da)
SI (1) SI3653227T1 (da)
WO (1) WO2016079114A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2896971T3 (es) * 2014-11-21 2022-02-28 Ascendis Pharma Endocrinology Div A/S Formas de administración de hormona del crecimiento de acción prolongada
CN109843295B (zh) 2016-09-29 2022-04-05 阿森迪斯药物生长障碍股份有限公司 控释cnp激动剂的组合疗法
AU2019246389A1 (en) * 2018-03-28 2020-08-27 Ascendis Pharma Oncology Division A/S IL-2 conjugates
WO2019185706A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugates
JP2022516308A (ja) 2019-01-04 2022-02-25 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス パターン認識受容体アゴニストのコンジュゲート
JP2022516314A (ja) 2019-01-04 2022-02-25 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス 自然免疫アゴニストのための持続性局所性薬物レベル
US20220054477A1 (en) 2019-01-04 2022-02-24 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
US20220054478A1 (en) 2019-01-04 2022-02-24 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
US20220088147A1 (en) * 2019-03-04 2022-03-24 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
EP4161956A1 (en) 2020-06-03 2023-04-12 Ascendis Pharma Oncology Division A/S Il-2 sequences and uses thereof
KR20230164709A (ko) 2021-04-01 2023-12-04 아센디스 파마 에이에스 염증 유발 질환을 치료하기 위한 지속형 성장 호르몬의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011197A (en) * 1997-03-06 2000-01-04 Infigen, Inc. Method of cloning bovines using reprogrammed non-embryonic bovine cells
EP1579873A1 (en) * 2004-03-23 2005-09-28 Complex Biosystems GmbH Polymeric prodrugs
CA2786794C (en) * 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
EP1625855A1 (en) * 2004-08-13 2006-02-15 Complex Biosystems GmbH Polymeric prodrug with a self-immolative linker
US20060233740A1 (en) * 2005-03-23 2006-10-19 Bossard Mary J Conjugates of an hGH moiety and a polymer
US9272048B2 (en) * 2008-04-29 2016-03-01 Ascendis Pharma Growth Disorders Division A/S PEGylated recombinant human growth hormone compounds
EP2113256A1 (en) * 2008-04-29 2009-11-04 Ascendis Pharma AS PEGylated rhGH compounds
ES2667025T3 (es) * 2009-12-15 2018-05-09 Ascendis Pharma Endocrinology Division A/S Composición seca de hormona de crecimiento unida transitoriamente a un portador de polímero
US20220088147A1 (en) * 2019-03-04 2022-03-24 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin

Also Published As

Publication number Publication date
RU2718664C2 (ru) 2020-04-13
IL251906B1 (en) 2023-12-01
NO2022014I1 (no) 2022-05-12
IL251906A0 (en) 2017-06-29
JP7431355B2 (ja) 2024-02-14
FIC20220017I1 (fi) 2022-06-03
JP7210683B2 (ja) 2023-01-23
SI3653227T1 (sl) 2021-04-30
JP2021020932A (ja) 2021-02-18
ES2947818T3 (es) 2023-08-21
IL251906B2 (en) 2024-04-01
HRP20210400T1 (hr) 2021-04-16
AU2015348633B2 (en) 2020-10-22
BR112017009798A2 (pt) 2017-12-19
EP4218823A2 (en) 2023-08-02
LT3653227T (lt) 2021-03-25
EP3653227B9 (en) 2023-03-08
EP3653227B3 (en) 2022-03-09
AU2020270494B2 (en) 2024-02-01
NL301172I1 (nl) 2022-04-29
PL3653227T6 (pl) 2022-04-19
JP6783782B2 (ja) 2020-11-11
HUS2200019I1 (hu) 2022-06-28
CY1123963T1 (el) 2022-05-27
FR22C1029I2 (fr) 2023-04-14
RS61734B1 (sr) 2021-05-31
KR102608645B1 (ko) 2023-12-01
DK3653227T6 (da) 2022-04-11
PL3653227T3 (pl) 2021-07-05
NZ731779A (en) 2021-11-26
AU2020270494A1 (en) 2020-12-17
IL307773A (en) 2023-12-01
RS61734B2 (sr) 2022-04-29
FR22C1029I1 (fr) 2022-09-09
MX2022009155A (es) 2022-08-16
EP3653227A1 (en) 2020-05-20
JP2023052300A (ja) 2023-04-11
ES2864415T9 (es) 2023-05-23
LTPA2022506I1 (da) 2022-06-10
US20200390864A1 (en) 2020-12-17
EP3653227B1 (en) 2021-01-20
SG10202105511RA (en) 2021-07-29
PT3653227T (pt) 2021-02-26
RU2017121203A3 (da) 2019-05-30
NL301172I2 (nl) 2022-06-16
AU2015348633C1 (en) 2021-02-11
ES2864415T3 (es) 2021-10-13
AU2024201227A1 (en) 2024-03-28
KR20170084267A (ko) 2017-07-19
HUE053855T2 (hu) 2021-07-28
JP2017535609A (ja) 2017-11-30
JP6982156B2 (ja) 2021-12-17
SG11201703870UA (en) 2017-06-29
HRP20210400T4 (hr) 2022-04-29
EP4218823A3 (en) 2023-11-15
DK3653227T3 (da) 2021-02-15
WO2016079114A1 (en) 2016-05-26
FI3237014T3 (fi) 2023-06-09
JP2022033787A (ja) 2022-03-02
KR20230152187A (ko) 2023-11-02
EP3237014A1 (en) 2017-11-01
DK3237014T3 (da) 2023-05-30
MX2017006113A (es) 2017-10-16
CA2968282A1 (en) 2016-05-26
EP3237014B1 (en) 2023-03-29
RU2017121203A (ru) 2018-12-19
US10799563B2 (en) 2020-10-13
US20170354716A1 (en) 2017-12-14
BR112017009798A8 (pt) 2020-11-03
JP2024054177A (ja) 2024-04-16
AU2015348633A1 (en) 2017-05-18
ES2864415T7 (es) 2022-05-12

Similar Documents

Publication Publication Date Title
DK3135609T3 (da) Artikeltransportanlæg
BR112016019329A2 (pt) produção de produtos de poliolefina.
DK3653227T3 (da) Hidtil ukendte polymere hgh-prodrugs
DK3182839T3 (da) Coating til fødevareprodukter
DK3167044T3 (da) Mikrofluidindretning
DK3237432T3 (da) Proteinfremstilling
BR112016018655A2 (pt) Linha de produtos de artigo absorvente
DK3341479T3 (da) LNA-G-Proces
DK3094579T3 (da) Bånd-på-bånd transportør
DK3097076T3 (da) Hidtil ukendte cyp-eicosanoidderivater
BR112017012635A2 (pt) produtos e métodos inovadores
DE112015005590A5 (de) Dosierpumpe
DE112016006709A5 (de) Nahrungsmittelherstellungsverfahren
DK3307076T3 (da) Podepartikelprodukt
FR3028721B3 (fr) Produit alimentaire
DK2933419T3 (da) Fenestration products
FI20160002A (fi) Tuote kuumennusta varten
TH1601002495A (th) กระบวนการสำหรับการปรับเปลี่ยนพอลิเมอร์
UA30928S (uk) Сушарка для харчових продуктів
UA32272S (uk) Кулінарний виріб
TH1501007055A (th) ผลิตภัณฑ์เครื่องรองเท้าและวิธีการสำหรับการก่อรูปผลิตภัณฑ์นั้น
UA30914S (uk) Ящик-лоток для хлібобулочних виробів
TH1401006892B (th) ผลิตภัณฑ์นาโนเคอร์คูมินที่ไวต่ออุณหภูมิ
FI10983U1 (fi) Rakennustuote
FI10787U1 (fi) Tuote